Setbacks in Alzheimer research demand new strategies, not surrender

1. “Pfizer ends research for new Alzheimer’s, Parkinson’s drugs” https://www.reuters.com/article/us-pfizer-alzheimers/pfizer-ends-research-for-new-alzheimers-parkinsons-drugs-idUSKBN1EW0TN Accessed Feb 8, 2018.

2. Prince M, Wilmo A, Guerchet M, Ali G, Wu Y, Prina M. World Alzheimer Report 2015: The global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimer’s Disease International. 2015. http://www.alz.co.uk/research/world-report-2015 Accessed Feb 8, 2018.

3. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014 Jan 23;370(4):311–21. doi: 10.1056/NEJMoa1312889 24450890

4. Honig L, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J Med 2018; 378:321–330 doi: 10.1056/NEJMoa1705971 29365294

5. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer’s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016 Dec 10;388(10062):2873–2884. doi: 10.1016/S0140-6736(16)31275-2 Epub 2016 Nov 16 27863809

6. White LR, Edland SD, Hemmy LS, Montine KS, Zarow C, Sonnen JA, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia Aging Studies. Neurology. 2016 Mar 15;86(11):1000–8. doi: 10.1212/WNL.0000000000002480 Epub 2016 Feb 17 26888993

7. Honda H, Sasaki K, Hamasaki H, Shijo M, Koyama S, Ohara T, et al. Trends in autopsy-verified dementia prevalence over 29 years of the Hisayama study. Neuropathology. 2016 Aug;36(4):383–7. doi: 10.1111/neup.12298 Epub 2016 Mar 14 26989005

8. Grinberg LT, Nitrini R, Suemoto CK, Lucena Ferretti-Rebustini RE, Leite RE, Farfel JM, et al. Prevalence of dementia subtypes in a developing country: a clinicopathological study. Clinics (Sao Paulo). 2013;68(8):1140–5. doi: 10.6061/clinics/2013(08)13 24037011

9. Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010. J Neuropathol Exp Neurol. 2012 Apr; 71(4): 266–273. doi: 10.1097/NEN.0b013e31824b211b 22437338

10. Desikan RS, Fan CC, Wang Y, Schork AJ, Cabral HJ, Cupples LA, et al. Genetic assessment of age-associated Alzheimer disease risk: development and validation of a polygenic hazard score. PLoS Med. 2017;14(3):e1002258. doi: 10.1371/journal.pmed.1002258 28323831

11. Steele NZ, Carr JS, Bonham LW, Geier EG, Damotte V, Miller ZA, et al. Fine-mapping of the human leukocyte antigen (HLA) locus as a risk factor for Alzheimer’s disease: A Case-Control Study. PLoS Med. 2017;14(3):e1002272. doi: 10.1371/journal.pmed.1002272 28350795

12. Wang H, MacDonald S, Dekhtyar S, Fratiglioni L. Association of lifelong exposure to cognitive reserve-enhancing factors with dementia risk: A community-based cohort study. PLoS Med. 2017;14(3):e1002251. doi: 10.1371/journal.pmed.1002251 28291786

13. Rusmaully J, Dugravot A, Moatti JP, Marmot MG, Elbaz A, Kivimaki M, et al. Contribution of cognitive performance and cognitive decline to associations between socioeconomic factors and dementia: A cohort study. PLoS Med. 2017;14(6):e1002334. doi: 10.1371/journal.pmed.1002334 28650972

14. Clare L, Wu Y-T, Teale JC, MacLeod C, Matthews F, Brayne C, et al. Potentially modifiable lifestyle factors, cognitive reserve, and cognitive function in later life: A cross-sectional study. PLoS Med. 2017;14(3): e1002259. doi: 10.1371/journal.pmed.1002259 28323829

15. Mendez MF. What is the Relationship of Traumatic Brain Injury to Dementia? J Alzheimers Dis. 2017;57(3):667–681. doi: 10.3233/JAD-161002 28269777

16. Nordström A and Nordström P. Traumatic brain injury and the risk of dementia diagnosis: A nationwide cohort study. PLoS Med. 2018;15(1):e1002496. doi: 10.1371/journal.pmed.1002496 29381704

17. Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial. PLoS Med. 2018;15(2):e1002500. doi: 10.1371/journal.pmed.1002500 29408901

18. Possin KL, Merrilees J, Bonasera SJ, Bernstein A, Chiong W, Lee K, et al. Development of an adaptive, personalized, and scalable dementia care program: Early findings from the Care Ecosystem. PLoS Med. 2017;14(3):e1002260. doi: 10.1371/journal.pmed.1002260 28323819